FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1489371507> ?p ?o ?g. }

• W1489371507 endingPage "178" @default.
• W1489371507 startingPage "167" @default.
• W1489371507 abstract "Object Although craniopharyngiomas are benign intracranial tumors, their high recurrence rates and intimate associations with surrounding neurovascular structures make gross tumor resection challenging. Stereotactic radiosurgery has been introduced as a valuable adjuvant therapy for recurrent or residual craniopharyngiomas. However, studies with large patient populations documenting long-term survival and progression-free survival rates are rare in the literature. The current study aims to report the long-term radiosurgical results and to define the prognostic factors in a large cohort of patients with a craniopharyngioma. Methods A total of 137 consecutive patients who underwent 162 sessions of Gamma Knife surgery (GKS) treatments at the Taipei Veterans General Hospital between 1993 and 2012 were analyzed. The patients' median age was 30.1 years (range 1.5–84.9 years), and the median tumor volume was 5.5 ml (range 0.2–28.4 ml). There were 23 solid (16.8%), 23 cystic (16.8%), and 91 mixed solid and cystic (66.4%) craniopharyngiomas. GKS was indicated for residual or recurrent craniopharyngiomas. The median radiation dose was 12 Gy (range 9.5–16.0 Gy) at a median isodose line of 55% (range 50%–78%). Results At a median imaging follow-up of 45.7 months after GKS, the rates of tumor control were 72.7%, 73.9%, and 66.3% for the solid, cystic, and mixed tumors, respectively. The actuarial progression-free survival rates plotted by the Kaplan-Meier method were 70.0% and 43.8% at 5 and 10 years after radiosurgery, respectively. After repeated GKS, the actuarial progression-free survival rates were increased to 77.3% and 61.2% at 5 and 10 years, respectively. The overall survival rates were 91.5% and 83.9% at the 5- and 10-year follow-ups, respectively. Successful GKS treatment can be predicted by tumor volume (p = 0.011). Among the 137 patients who had clinical follow-up, new-onset or worsened pituitary deficiencies were detected in 11 patients (8.0%). Two patients without tumor growth had a worsened visual field, and 1 patient had a new onset of third cranial nerve palsy. Conclusions The current study suggests that GKS is a relatively safe modality for the treatment of recurrent or residual craniopharyngiomas, and it is associated with improved tumor control and reduced in-field recurrence rates. Acceptable rates of complications occurred." @default.
• W1489371507 created "2016-06-24" @default.
• W1489371507 creator A5001959228 @default.
• W1489371507 creator A5006288322 @default.
• W1489371507 creator A5006571598 @default.
• W1489371507 creator A5012933713 @default.
• W1489371507 creator A5035839892 @default.
• W1489371507 creator A5046359356 @default.
• W1489371507 creator A5059303705 @default.
• W1489371507 creator A5062529388 @default.
• W1489371507 creator A5063738165 @default.
• W1489371507 creator A5074737496 @default.
• W1489371507 date "2014-12-01" @default.
• W1489371507 modified "2023-10-16" @default.
• W1489371507 title "Gamma Knife surgery for craniopharyngioma: report on a 20-year experience" @default.
• W1489371507 cites W1523496381 @default.
• W1489371507 cites W1593251552 @default.
• W1489371507 cites W1928904918 @default.
• W1489371507 cites W1949937918 @default.
• W1489371507 cites W1966239792 @default.
• W1489371507 cites W1981640678 @default.
• W1489371507 cites W1984610816 @default.
• W1489371507 cites W1989416923 @default.
• W1489371507 cites W1991395695 @default.
• W1489371507 cites W1995268159 @default.
• W1489371507 cites W1996566139 @default.
• W1489371507 cites W2006279875 @default.
• W1489371507 cites W2006366428 @default.
• W1489371507 cites W2006834596 @default.
• W1489371507 cites W2007025727 @default.
• W1489371507 cites W2008287890 @default.
• W1489371507 cites W2011268583 @default.
• W1489371507 cites W2012572621 @default.
• W1489371507 cites W2013961566 @default.
• W1489371507 cites W2019768591 @default.
• W1489371507 cites W2020012585 @default.
• W1489371507 cites W2028838806 @default.
• W1489371507 cites W2029874986 @default.
• W1489371507 cites W2033783624 @default.
• W1489371507 cites W2044063639 @default.
• W1489371507 cites W2047928566 @default.
• W1489371507 cites W2052505840 @default.
• W1489371507 cites W2060609894 @default.
• W1489371507 cites W2065423896 @default.
• W1489371507 cites W2072570048 @default.
• W1489371507 cites W2073745077 @default.
• W1489371507 cites W2074352859 @default.
• W1489371507 cites W2075888676 @default.
• W1489371507 cites W2083182636 @default.
• W1489371507 cites W2088210800 @default.
• W1489371507 cites W2121007115 @default.
• W1489371507 cites W2148387618 @default.
• W1489371507 cites W2148596299 @default.
• W1489371507 cites W2155098336 @default.
• W1489371507 cites W2157103884 @default.
• W1489371507 cites W2161567204 @default.
• W1489371507 cites W2172172630 @default.
• W1489371507 cites W3022251977 @default.
• W1489371507 cites W4211158091 @default.
• W1489371507 cites W4251966453 @default.
• W1489371507 doi "https://doi.org/10.3171/2014.8.gks141411" @default.
• W1489371507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25434950" @default.
• W1489371507 hasPublicationYear "2014" @default.
• W1489371507 type Work @default.
• W1489371507 sameAs 1489371507 @default.
• W1489371507 citedByCount "62" @default.
• W1489371507 countsByYear W14893715072015 @default.
• W1489371507 countsByYear W14893715072016 @default.
• W1489371507 countsByYear W14893715072017 @default.
• W1489371507 countsByYear W14893715072018 @default.
• W1489371507 countsByYear W14893715072019 @default.
• W1489371507 countsByYear W14893715072020 @default.
• W1489371507 countsByYear W14893715072021 @default.
• W1489371507 countsByYear W14893715072022 @default.
• W1489371507 countsByYear W14893715072023 @default.
• W1489371507 crossrefType "journal-article" @default.
• W1489371507 hasAuthorship W1489371507A5001959228 @default.
• W1489371507 hasAuthorship W1489371507A5006288322 @default.
• W1489371507 hasAuthorship W1489371507A5006571598 @default.
• W1489371507 hasAuthorship W1489371507A5012933713 @default.
• W1489371507 hasAuthorship W1489371507A5035839892 @default.
• W1489371507 hasAuthorship W1489371507A5046359356 @default.
• W1489371507 hasAuthorship W1489371507A5059303705 @default.
• W1489371507 hasAuthorship W1489371507A5062529388 @default.
• W1489371507 hasAuthorship W1489371507A5063738165 @default.
• W1489371507 hasAuthorship W1489371507A5074737496 @default.
• W1489371507 hasBestOaLocation W14893715071 @default.
• W1489371507 hasConcept C10515644 @default.
• W1489371507 hasConcept C105572291 @default.
• W1489371507 hasConcept C126322002 @default.
• W1489371507 hasConcept C126838900 @default.
• W1489371507 hasConcept C141071460 @default.
• W1489371507 hasConcept C2777047896 @default.
• W1489371507 hasConcept C2780387249 @default.
• W1489371507 hasConcept C2989005 @default.
• W1489371507 hasConcept C509974204 @default.
• W1489371507 hasConcept C71924100 @default.
• W1489371507 hasConcept C72563966 @default.

• next